Landos Biopharma, Inc. (LABP)
Market Cap | 10.67M |
Revenue (ttm) | n/a |
Net Income (ttm) | -39.28M |
Shares Out | 40.25M |
EPS (ttm) | -0.98 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 40,554 |
Open | 0.243 |
Previous Close | 0.260 |
Day's Range | 0.243 - 0.277 |
52-Week Range | 0.211 - 1.920 |
Beta | -1.13 |
Analysts | Sell |
Price Target | 2.75 (+937.74%) |
Earnings Date | May 10, 2023 |
About LABP
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis; NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1 (NOD-like), a mitochondria-associated receptor assoc... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for LABP stock is "Sell." The 12-month stock price forecast is $2.75, which is an increase of 937.74% from the latest price.
News

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results
On Track to Initiate Phase 2 Proof-of-Concept Trial in Ulcerative Colitis for NX-13 in the Second Quarter of 2023 and Report Topline Results by the Fourth Quarter of 2024

Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos' Founder
Transaction Solidifies Company's Near-Term Strategic Focus on Advancing Clinical Development of NX-13

Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn's and Colitis Organization
Company Remains On-Track to Initiate Phase 2 Proof-of-Concept Clinical Trial in Second Quarter of 2023 Company Remains On-Track to Initiate Phase 2 Proof-of-Concept Clinical Trial in Second Quarter of...

Landos Biopharma Provides Comprehensive Update on Clinical Development Plans
Advancing NX-13 Clinical Development for Treatment of Ulcerative Colitis

Landos Biopharma Announces $16.7 Million Private Placement Financing
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients ...

Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update
On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming Weeks On Track to Complete Comprehensive Review of Clinical Development Plans in the Coming Weeks

Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update
Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range of Once-Daily Oral Doses, as well as Promising Early Effi...

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates
Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
Continued Progress Towards Optimizing Clinical Development Plans

Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization

Should You Buy Landos Biopharma (LABP) Ahead of Earnings?
Landos Biopharma (LABP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Landos Biopharma Announces Leadership Transition
Josep Bassaganya-Riera Steps Down as Chairman, President and CEO

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis
Phase 1 trial is underway with topline results expected in the first half of 2022

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus
Phase 1 trial initiation expected before yearend with topline results in 1H 2022

Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancor's Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism
BLACKSBURG, Va., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and de...

Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohn's Disease with the Icahn School of Medicine at Mount Sinai
Second Phase 2 trial of omilancor in Crohn's disease (CD), expected to initiate in 2021

Landos Biopharma to Participate in Two Upcoming Investor Conferences in September
BLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel ...

Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine
BLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel o...

Landos Biopharma to Participate in Upcoming Investor Events
BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel o...

Landos Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Updates
Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated global pivotal Phase 3 clinical trial site feasibility studies of omilancor in ulcerative colitis (UC)

Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference
BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and dev...

Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis (UC) Patients
The FDA clears the path to initiate the PACIFY I and II global registration studies in Mild-to-Moderate Active UC patients representing the potential for a broad product label for Omilancor The FDA cl...

Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference
BLACKSBURG, Va., May 25, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop novel...

Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors
BLACKSBURG, Va., May 19, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients...

Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China
Landos Biopharma Inc (NASDAQ: LABP) and LianBio have announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China (mainl...